Učitavanje...
Inotuzumab Ozogamicin Versus Standard Care for Acute Lymphoblastic Leukemia
BACKGROUND: Inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, is active in acute lymphoblastic leukemia. METHODS: In this phase 3 trial, adults with relapsed/refractory acute lymphoblastic leukemia were randomized to inotuzumab ozogamicin or standard intensive chemotherapy. P...
Spremljeno u:
| Izdano u: | N Engl J Med |
|---|---|
| Glavni autori: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5594743/ https://ncbi.nlm.nih.gov/pubmed/27292104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1509277 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|